Global Antibiotic Research and Development Partnership (GARDP)

The Global Antibiotic Research and Development Partnership (GARDP) aims to develop and deliver new treatments for bacterial infections where drug resistance is present or emerging, or for which inadequate treatment exists, while endeavoring to ensure sustainable access.

Antimicrobial resistance (AMR) is a major and rapidly growing global public health concern. Serious bacterial infections resistant to antibiotic treatment have been identified by the World Health Organization as a global public health priority. As a response to this serious danger to Global Health, GARDP was established in May 2016 as a not-for-profit research and development initiative by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi). GARDP works largely as a virtual research and development (R&D) initiative through direct partnerships and multi-stakeholder collaborations, including with academia, industry, international organizations and governments. The approach is to develop drugs from any point from early exploratory to preclinical and clinical studies all the way to patients, always having access and stewardship measures embedded. GARDP works to address global public health needs including for low- and middle-income countries and ensures that new antibiotics developed are made available at an affordable price to all in need.

BMBF is providing leadership in addressing AMR

GARDP’s strategy for antibiotic drug development comprises a mix of short- and longer-term approaches to tackle immediate needs and to work on sustainable solutions to pressing public health needs. The € 50 million investment of the German Federal Ministry of Education and Research (BMBF) provides vital support for GARDP’s business activities. Specifically, GARDP will use the BMBF funds to advance the following areas of its R&D portfolio:

  • Sexually-transmitted Infections (STIs): GARDP has developed a roadmap to treat STIs, starting with a focus on gonorrhoea. Latest WHO data shows that more than 60% of countries surveyed across the world have reported resistance to last-line antibiotics. In partnership with a company, GARDP plans to co-develop zoliflodacin, one of the few drugs in the pipeline to treat drug resistant gonorrhoea, in a global Phase III clinical trial.
  • Neonatal Sepsis: An estimated 214.000 neonatal sepsis deaths each year are believed to result from drug-resistant infections. GARDP will initiate work to develop new treatment regimens for babies with neonatal sepsis.
  • Paediatric Antibiotic Platform: This programme aims to optimize current treatments and accelerate the development of new antibiotics specifically adapted for children, through an R&D programme which expects to include a network of clinical trials.
  • Antimicrobial Memory Recovery and Exploratory programme: The Memory Recovery programme will engage more than 100 world-class experts in its bid to recoup essential knowledge and lost memory of abandoned antibiotic development projects to help identify new drug opportunities. A digital hub, “REVIVE”, will provide a space for experts and new researchers to network and learn.